drugset / Trial / NCT01263080

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

NCT01263080

Phase 4 Completed 333 enrolled Capital Medical University
RandomizedFactorialDouble-blindTreatment

Summary

Multicentre randomised double-blind, placebo-controlled 2x2 factorial trial investigating the effects of adding mirtazapine and folic acid to existing therapy for patients with schizophrenia

Timeline

Start
2010-11
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirtazapine Other / unclassified 30 mg
Comparator folic acid Other / unclassified 0.4 mg

Indications